INVESTIGATION ALERT: Schall Law Firm Announces It is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors Who Have Suffered Losses to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or “the Company “) (NASDAQ: YMAB) for violating securities laws.

The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. Y-mAbs is the subject of disclosure documents posted on the FDA website on October 26, 2022. According to the documents, FDA scientists have identified concerns with the data submitted as part of the license application. biologics (BLA) for omburtamab. The FDA identified several issues with the company’s data, including differences between its study and control populations. Based on this news, shares of Y-mAbs fell more than 23% in intraday trading on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by e-mail at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.

Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethical requirements.